This strategy could enhance the efficacy of immunotherapies by increasing tumor immunogenicity, thereby improving responsiveness to treatments such as immune checkpoint inhibitors and macrophage-targeted therapies, including CSF1R and TREM2 inhibitors. This evidence concerns the gene CSF1R and neoplasm.